Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | NPC1 | O15118 | 3/20 | 0.71 |
| ▸ | RAB9A | P51151 | 2/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | JAK2 | O60674 | 2/20 | 0.52 |
| ▸ | JAK1 | P23458 | 2/20 | 0.52 |
| ▸ | TYK2 | P29597 | 2/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.51 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.51 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.51 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.51 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.51 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933206 | 1.00 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1 | |
| SCHEMBL3277860 | 1.00 | SMN1; SMN2 (0.71) | SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1 | |
| SCHEMBL14630820 | 0.96 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1 | |
| SCHEMBL10565545 | 0.96 | SMN1; SMN2 (0.69) | SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1 | |
| Toluene SCHEMBL27971647 | 0.94 | SMN1; SMN2 (0.63) | SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1 | |
| SCHEMBL12070966 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL2330005 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL103560 | 0.92 | SMN1; SMN2 (0.84) | SMN1; SMN2NPC1RAB9ACYP2C19MEN1 | |
| SCHEMBL1437372 | 0.90 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1 | |
| SCHEMBL13133558 | 0.90 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 334 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105130879-B | （R）The preparation method of 3 Boc amino piperidines | 沧州那瑞化学科技有限公司 | 2018-03-02 | — | — | CN | claimed |
| CN-105130879-A | Preparation method of (R)-3-Boc-aminopiperidine | CANGZHOU SENARY CHEMICAL SCIENCE TEC CO LTD | 2015-12-09 | — | — | CN | claimed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4648851-A1 | SUBSTITUTED (HETERO)ANILINES AND THEIR USE | Astrazeneca AB (SE) | 2025-11-19 | — | — | EP | disclosed |
| EP-3236959-B1 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 7 (CDK7) | DANA FARBER CANCER INST INC (US) | 2025-09-24 | — | — | EP | disclosed |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-07-03 | — | — | US | disclosed |
| EP-4499149-A1 | PROTEIN DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | disclosed |
| WO-2025007863-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | 深圳市塔吉瑞生物医药有限公司 | 2025-01-09 | — | — | WO | disclosed |
| CN-119241532-A | 1H-pyrazolo [4,3-c ] pyridine compound, composition and application thereof | 深圳市塔吉瑞生物医药有限公司 | 2025-01-03 | — | — | CN | disclosed |
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-11-07 | — | — | US | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0623596-A1 | N-acylpyrrolidines or N-acylpiperidines having a guanidinyl- or amidinyl-substituted side chain as thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-11-09 | — | — | EP | disclosed |
| EP-0520336-A2 | Aldehyde derivatives and their use as calpain inhibitors | FUJIREBIO Inc. (JP) | 1992-12-30 | — | — | EP | disclosed |
| US-4564623-A | HISTAMINE H2-ANTAGONISTS, ANTIULCER AGENTS | SHIONOGI & CO., LTD. (JP) | 1986-01-14 | — | — | US | disclosed |
| US-4482566-A | ANTIULCER AGENTS | TEIKOKU HORMONE MFG. CO., LTD. (JP) | 1984-11-13 | — | — | US | disclosed |
| EP-0023578-B1 | AMINOALKYLBENZENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS | SHIONOGI & CO., LTD. (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4309433-A | TREATMENT OF PEPTIC ULCERS | SHIONOGI & CO., LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| US-4022792-A | ANALGESICS | STERLING DRUG INC. (US) | 1977-05-10 | — | — | US | disclosed |
| US-3976653-A | ANALGESIC ANTAGONIST | STERLING DRUG INC. (US) | 1976-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168663-B2 | Inhibitors of cyclin-dependent kinase 7 (CDK7) | CDK7, CDK3, CDK9 | SMN1; SMN2 1868/4885NPC1 4352/4885RAB9A 1269/4885 |
| US-20240368150-A1 | BICYCLIC TETRAHYDROAZEPINE DERIVATIVES FOR THE TREATMENT OF CANCER | BICRA, BRD4, CNR1 | SMN1; SMN2 3375/4885NPC1 1363/4885RAB9A 1690/4885 |
| US-20250214969-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | SMN1; SMN2 1231/4885NPC1 2433/4885RAB9A 2718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.